Katsuhiro Uto

Katsuhiro Uto served as Chief Executive Officer of FIMECS, Inc. in 2025 and held the Board Member role there. At RaQualia Pharma Inc., Uto held multiple roles, including VP, Board Member, Head of Discovery Research (2022–2023), and also served as Board Member, VP of Research Planning, Director of Research Planning, and VP, Board Member, Head of R&D. Earlier experience includes Postdoctoral Researcher at Kyushu University (2001–2005), Research Scientist at Boehringer Ingelheim (2005–2012), Research Manager at Asahi Kasei Pharma (2013–2017), Senior Project Manager at Maruho Co., Ltd (2018–2020), and a Research Manager role. Their education includes a BS in Biology (1992–1996), an MS in Developmental Biology and Embryology (1996–1998), and a PhD in Molecular Biology, Developmental Biology and Embryology (1998–2001) from Kyushu University.